Immunocore Holdings plc (IMCR) stock price, news, quote and history

Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

Immunocore reports Q3 KIMMTRAK revenue of $102.2 million By Investing.com

Immunocore Reports Q3 2026 Revenue of $102.2 Million and $14.2 Million Net Loss

Revenue fell 1.4% at Immunocore (IMCR), while its quarterly loss widened.

Immunocore reports third quarter financial results and provides a business update

Immunocore Hldgs Q3 EPS $(0.28) Misses $(0.10) Estimate, Sales $102.222M Miss $113.438M Estimate

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

Immunocore To Present Phase 1/2 Trial Data Evaluating Brenetafusp Alone And In Combination With KIMMTRAK In HLA-A*02:01-Positive Patients With Metastatic Uveal Melanoma, At 2026 SITC Annual Meeting

Should First Type 1 Diabetes Dosing Require Action From Immunocore Stock Investors?

HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target

GeneDx Holdings And 2 Other Top Healthcare Stocks

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

Top 3 Healthcare Stocks To Watch In October 2026

Immunocore: Advanced Cutaneous Melanoma Data Catalysts Feel Crucial (NASDAQ:IMCR)